NEWS

Our HospitalAnalyzer is now available!

  • Published at 11.01.2023
  • Reading time 1 Min.

Based on the quality assurance data of the G-BA, we provide analyses on German hospitals for your market planning.

For example: What are the top hospitals for AML in remission (C92.01 according to ICD-10)?

Top 5 Hospitals:

  • University Medical Center of Johannes Gutenberg University Mainz
  • University Hospital Giessen and Marburg, Giessen site
  • Municipal Hospital Braunschweig
  • Klinikum Bremen-Mitte
  • Klinikum Darmstadt

Overall, 113 German hospitals have reported the indication in the quality assurance data.

We analyze for you:

  • For your market planning: in which hospitals are your patients found?
  • How many hospitals have a specific diagnosis?
  • How often did hospitals use a procedure of your interest?
  • Which hospital departments have reported your indication and who are the relevant contacts?

Feel free to contact us for further information!

 

More posts

Deep Dive: Price-Volume Model (§130b)

The price-volume regulation shall no longer be subject to arbitration. The default mechanism kicks in if no agreement between the pharmaceutical company and the statutory health insurances is reached and adjusts the reimbursement amount annually (starting in the third calendar year after launch) usi…

Read post

Draft Bill BStabG: What Matters for Pharmaceutical Companies now

The current draft bill on statutory health insurance contribution rate stabilization (BStabG) sets out the health policy objective of tighter expenditure control — with direct implications for pricing, market access, and reimbursement in the German market. An overview of the key changes for innovati…

Read post

Pediatric drug shortages

Pediatric drug shortages: has the situation really improved? In recent years, Germany has faced shortages of essential medicines for children, including antipyretics and antibiotics. To encourage manufacturers to increase production and supply, the GKV-SV (GKV-Spitzenverband, German SHI association)…

Read post

Start of EU-HTA: First Joint Assessments with IQWiG Involvement

Since the beginning of 2025, member states of the European Economic Area (EEA) have been working together on joint clinical assessments (JCA) of new medicines. Recently, the first 9 JCAs were announced, assessing 2 ATMPs with Orphan drug status and 7 oncologics. Germany, France, and Ireland are curr…

Read post